These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

468 related items for PubMed ID: 18098337

  • 1. BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations.
    Preto A, Figueiredo J, Velho S, Ribeiro AS, Soares P, Oliveira C, Seruca R.
    J Pathol; 2008 Feb; 214(3):320-7. PubMed ID: 18098337
    [Abstract] [Full Text] [Related]

  • 2. Concomitant RASSF1A hypermethylation and KRAS/BRAF mutations occur preferentially in MSI sporadic colorectal cancer.
    Oliveira C, Velho S, Domingo E, Preto A, Hofstra RM, Hamelin R, Yamamoto H, Seruca R, Schwartz S.
    Oncogene; 2005 Nov 17; 24(51):7630-4. PubMed ID: 16007118
    [Abstract] [Full Text] [Related]

  • 3. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins.
    Friday BB, Yu C, Dy GK, Smith PD, Wang L, Thibodeau SN, Adjei AA.
    Cancer Res; 2008 Aug 01; 68(15):6145-53. PubMed ID: 18676837
    [Abstract] [Full Text] [Related]

  • 4. Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer.
    Zlobec I, Kovac M, Erzberger P, Molinari F, Bihl MP, Rufle A, Foerster A, Frattini M, Terracciano L, Heinimann K, Lugli A.
    Int J Cancer; 2010 Dec 01; 127(11):2569-75. PubMed ID: 20162668
    [Abstract] [Full Text] [Related]

  • 5. Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations.
    Preto A, Gonçalves J, Rebocho AP, Figueiredo J, Meireles AM, Rocha AS, Vasconcelos HM, Seca H, Seruca R, Soares P, Sobrinho-Simões M.
    BMC Cancer; 2009 Oct 31; 9():387. PubMed ID: 19878585
    [Abstract] [Full Text] [Related]

  • 6. B-Raf(V600E) cooperates with alternative spliced Rac1b to sustain colorectal cancer cell survival.
    Matos P, Oliveira C, Velho S, Gonçalves V, da Costa LT, Moyer MP, Seruca R, Jordan P.
    Gastroenterology; 2008 Sep 31; 135(3):899-906. PubMed ID: 18602919
    [Abstract] [Full Text] [Related]

  • 7. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B, Knauf JA, Smith EP, Zhang L, Ramsey T, Yusuff N, Batt D, Fagin JA.
    Clin Cancer Res; 2006 Mar 15; 12(6):1785-93. PubMed ID: 16551863
    [Abstract] [Full Text] [Related]

  • 8. KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression.
    Oliveira C, Velho S, Moutinho C, Ferreira A, Preto A, Domingo E, Capelinha AF, Duval A, Hamelin R, Machado JC, Schwartz S, Carneiro F, Seruca R.
    Oncogene; 2007 Jan 04; 26(1):158-63. PubMed ID: 16953233
    [Abstract] [Full Text] [Related]

  • 9. Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma.
    Kumar SM, Yu H, Edwards R, Chen L, Kazianis S, Brafford P, Acs G, Herlyn M, Xu X.
    Cancer Res; 2007 Apr 01; 67(7):3177-84. PubMed ID: 17409425
    [Abstract] [Full Text] [Related]

  • 10. BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis?
    Velho S, Moutinho C, Cirnes L, Albuquerque C, Hamelin R, Schmitt F, Carneiro F, Oliveira C, Seruca R.
    BMC Cancer; 2008 Sep 09; 8():255. PubMed ID: 18782444
    [Abstract] [Full Text] [Related]

  • 11. Oncogenic Ras, but not (V600E)B-RAF, protects from cholesterol depletion-induced apoptosis through the PI3K/AKT pathway in colorectal cancer cells.
    Calleros L, Sánchez-Hernández I, Baquero P, Toro MJ, Chiloeches A.
    Carcinogenesis; 2009 Oct 09; 30(10):1670-7. PubMed ID: 19700418
    [Abstract] [Full Text] [Related]

  • 12. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.
    Seth R, Crook S, Ibrahem S, Fadhil W, Jackson D, Ilyas M.
    Gut; 2009 Sep 09; 58(9):1234-41. PubMed ID: 19474002
    [Abstract] [Full Text] [Related]

  • 13. Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells.
    Takezawa K, Okamoto I, Yonesaka K, Hatashita E, Yamada Y, Fukuoka M, Nakagawa K.
    Cancer Res; 2009 Aug 15; 69(16):6515-21. PubMed ID: 19638574
    [Abstract] [Full Text] [Related]

  • 14. Oligonucleotide microarray analysis of distinct gene expression patterns in colorectal cancer tissues harboring BRAF and K-ras mutations.
    Kim IJ, Kang HC, Jang SG, Kim K, Ahn SA, Yoon HJ, Yoon SN, Park JG.
    Carcinogenesis; 2006 Mar 15; 27(3):392-404. PubMed ID: 16219636
    [Abstract] [Full Text] [Related]

  • 15. BRAF is a therapeutic target in aggressive thyroid carcinoma.
    Salvatore G, De Falco V, Salerno P, Nappi TC, Pepe S, Troncone G, Carlomagno F, Melillo RM, Wilhelm SM, Santoro M.
    Clin Cancer Res; 2006 Mar 01; 12(5):1623-9. PubMed ID: 16533790
    [Abstract] [Full Text] [Related]

  • 16. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia.
    Yuen ST, Davies H, Chan TL, Ho JW, Bignell GR, Cox C, Stephens P, Edkins S, Tsui WW, Chan AS, Futreal PA, Stratton MR, Wooster R, Leung SY.
    Cancer Res; 2002 Nov 15; 62(22):6451-5. PubMed ID: 12438234
    [Abstract] [Full Text] [Related]

  • 17. The influence of the BRAF V600E mutation in thyroid cancer cell lines on the anticancer effects of 5-aminoimidazole-4-carboxamide-ribonucleoside.
    Choi HJ, Kim TY, Chung N, Yim JH, Kim WG, Kim JA, Kim WB, Shong YK.
    J Endocrinol; 2011 Oct 15; 211(1):79-85. PubMed ID: 21795305
    [Abstract] [Full Text] [Related]

  • 18. Increased cancer predisposition in family members of colorectal cancer patients harboring the p.V600E BRAF mutation: a population-based study.
    Wish TA, Hyde AJ, Parfrey PS, Green JS, Younghusband HB, Simms MI, Fontaine DG, Dicks EL, Stuckless SN, Gallinger S, McLaughlin JR, Woods MO, Green RC.
    Cancer Epidemiol Biomarkers Prev; 2010 Jul 15; 19(7):1831-9. PubMed ID: 20570909
    [Abstract] [Full Text] [Related]

  • 19. BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid <or=1 cm and their paired lymph node metastases.
    Rodolico V, Cabibi D, Pizzolanti G, Richiusa P, Gebbia N, Martorana A, Russo A, Amato MC, Galluzzo A, Giordano C.
    Cancer; 2007 Sep 15; 110(6):1218-26. PubMed ID: 17685465
    [Abstract] [Full Text] [Related]

  • 20. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
    Vakana E, Pratt S, Blosser W, Dowless M, Simpson N, Yuan XJ, Jaken S, Manro J, Stephens J, Zhang Y, Huber L, Peng SB, Stancato LF.
    Oncotarget; 2017 Feb 07; 8(6):9251-9266. PubMed ID: 27999210
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.